GlaxoSmithKline Pharmaceuticals : records 11% Sales growth for Q4, FY 2016-17

Friday, 19thMay 2017, Mumbai

-------------------------------------------------------------------------------

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the year and quarter ended 31stMarch 2017.

Sales for the quarter ended 31stMarch 2017 at Rs.763 crores recorded a growth of 11% as compared to the same prior year period. Profit Before Tax (PBT) at Rs. 170 crores and Profit After Tax (PAT) at

Rs 113 crores grew by 4% and 6% respectively against the same prior year period. The quarterly Sales growth rate was adversely impacted by 6% from a series of mandatory price revisions on products under price control that took place during the year ending March 2017.

Sales for the year ended 31stMarch 2017 at Rs.2921 crores recorded a growth of 6% as compared to the same prior year period. Profit Before Tax (PBT) at Rs.511 crores and Profit After Tax (PAT) at Rs 337 crores declined by 11% and 10% respectively as compared to the same prior year period. The annual Sales growth rate was adversely impacted by 5% from the mandatory price revisions.

The Board of Directors of the Company recommended a Dividend at the rate of Rs. 30 per equity share of Rs. 10 each for the 12 month period ended March 31st, 2017.

"Our financial performance highlights a double digit quarterly Sales growth underpinned by a strong volume momentum in our endeavour to bring affordable medicine to Indian patients.

The recently launched probiotic food supplement EnteroPlus™, the combination vaccines for measles, mumps, rubella and varicella, Priorix Tetra™, as well as the restored manufacturing of Neosporin ®, an antibiotic to treat minor wounds, are all gaining strong momentum within their therapeutic categories.

The optimisation of costs contributed to an EBITDA margin of 18% in the quarter, despite the adverse impact from price reductions. Furthermore, the company enhanced its profitability in the quarter with an exceptional income from the disposal of non-core assets totalling Rs 26 crores."

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com

Media Contacts: Ransom D'Souza Vice President

Communications & Government Affairs Email: ransom.a.dsouza@gsk.com Tel: +91 22 24959203